Background: Recent studies have reported that anti-tumour necrosis factor (anti-TNF) blockers alone or in combination with immunomodulators (IM) can impair the serological response to pneumococcal vaccination in patients with inflammatory bowel disease (IBD). However, the type of IBD might have been a potential confounding factor in the previous studies. Therefore, we evaluated the effect of immunosuppressive treatment on the serological response to and safety of the 23-valent pneumococcal polysaccharide vaccine in patients with Crohn's disease. Methods: This is part of an on-going prospective, multicentre, observational study. Of 180 patients enrolled, 171 completed the study. The study population belonged to one of the following four treatment groups: 5-aminosalicylate alone (control group, n = 37), IM alone (IM group, n = 70), anti-TNF blocker alone (anti-TNF group, n = 14), and anti-TNF blocker in combination with IM (combination group, n = 50). Antipneumococcal IgG antibody titres were measured before and 4 weeks after vaccination. The primary outcome was the serological response rate, defined as the proportion of patients achieving both a twofold increase in baseline titres and a post-vaccination geometric mean titre (GMT) 1 mg/mL. The secondary outcome was the difference in the GMTs prior to and after vaccination. All vaccination-related adverse events up to 4 weeks after vaccination were recorded. This study is registered at www.clinicaltrials.gov (NCT01505855). Results: The overall serological response rate was 70.8% (121/170). Only the combination group had a significantly lower serological response rate than did the control group (58.0% vs. 78.4%, P < 0.05). The post-vaccination GMTs of the immunosuppressed patients were significantly lower than that of the non-immunosuppressed patients (P < 0.001). The postvaccination GMTs did not differ significantly among the IM, anti-TNF, and combination groups (P > 0.05). Vaccination was generally safe and well-tolerated by all patients. Conclusions: Only treatment with the combination of anti-TNF and IM led to impaired seroprotection to pneumococcal vaccination in patients with Crohn's disease. Patients receiving immunosuppressive therapies had significantly lower postvaccination GMTs than did non-immunosuppressed patients, suggesting that the use of immunosuppressive medications, regardless of their types, could be a potential cause of suboptimal response to pneumococcal vaccination.
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Conclusions: Anti TNF therapy in IBD patients is secure, with 10 13% of side effects accordingly to our study, where the most frequent type were minor side effects, although there still exist serious complications. It is fundamental a strictly follow up of patient with Anti TNF therapy.
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1 IRCCS "S. De Belllis", Gastroenterology and Digestive Endoscopy, Castellana Grotte, Italy Background: In the past 10 years, the Oxford regimen, based on the use of intravenous corticosteroids, has been modified by the introduction of cyclosporine (CyS) and infliximab (IFX) as treatment options of severe ulcerative colitis (UC). Long term prognosis, in CyS treated patients, is reported to be improved by the introduction of azathioprine (AZA) or mercaptopurine (6-MP) in association with oral CyS as bridge therapy. We report long-term follow-up results from an openlabel study that assessed the efficacy and safety of oral CyS in steroid refractory-naïve patients with moderately to severely active UC. Methods: 17 patients (pts) (9 male, 8 female, aged 19 72 years), steroids and AZA/6-MP treatment naïve, received oral CyS as rescue therapy for acute UC, following 2 9 days of intravenous steroids (1 mg/kg/per day); pts were commenced on 5 mg/kg/per day of oral CyS (T0). After 2 weeks all the pts received AZA treatment (2 mg/kg/per day); all the pts followed their 5-ASA therapy (dose ranging 2.4 3.6 g/per day) and tapered steroids 5 mg/every week. The clinical assessment was evaluated with Mayo Scoring System for Assessment of UC Activity; clinical remission was defined as an inactive score and response was defined as an improvement of the activity score after 6 weeks of CyS treatment (T6).
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